• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Proscia Raises $8M for AI-Enhanced Digital Pathology for Cancer Diagnosis

by Jasmine Pennic 09/26/2018 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Proscia Raises $8M for AI-Enhanced Digital Pathology for Cancer Diagnosis

Proscia, a Philadelphia-based digital pathology platform has raised $8.3 million in Series A funding led by Boston-based Flybridge Capital Partners with participation from Emerald Development Managers, Fusion Fund, Razor’s Edge Ventures, and RobinHood Ventures.

The startup plans to utilize the Series A funding to fuel the development and commercialization of new, clinical AI-enabled workflows targeting high-volume, high-impact cancers, the first of which will be available later this year. In addition, Proscia will also use the funds to ramp up sales and marketing of its existing cloud-based digital pathology platform, which will serve as the foundation for Proscia’s AI-based applications. 

Pathology is at the center of cancer diagnosis and guides a patient’s entire cancer journey, yet pathologists and their ability to diagnose cancer are largely dependent on the microscope that has been in place for 150 years. The limitations of the microscope and the subjectivity involved in assessing tumors contribute to diagnostic error, resulting in negative patient outcomes and economic burden to the healthcare system. 

Founded in 2014 by a team of clinicians at Johns Hopkins and the University of Pittsburgh, Proscia’s digital pathology platform is currently used by thousands of pathologists, scientists, histotechnicians, and lab managers at more than 300 clinical and research facilities worldwide, including, Driver, Henry Ford Health System, Hospital Puerto Montt, Johns Hopkins Department of Pathology, and Thomas Jefferson University Hospitals. The cloud-based, modular platform integrates easily with labs’ unique environments and complex technology ecosystems, enabling them to:

– Adopt digital pathology on their own terms by rolling out new features and capabilities seamlessly as they embark on the path to AI-enhanced pathology

– Create new image-based workflows that streamline operations, reduce turnaround times, and cut costs

– Open up new imaging and analytics revenue streams to differentiate themselves from their peers and thrive in the current climate of rapid laboratory and hospital consolidation

– Protect and future-proof current investments in hardware and other infrastructure

– Improve diagnostic efficiency and quality to ultimately improve patient outcomes

Proscia represents a paradigm shift, using the image analysis capabilities of machines to augment human evaluations for better, more reliable diagnosis. Facing intense economic pressure, a shrinking workforce and a surge in the global demand for pathology, laboratory medicine is primed for a shift to digital and AI-driven methods. The This platform will serve as the launchpad for a series of AI-enabled, disease-specific modules, the first of which, DermAI™, will be released in December 2018.

“Digital pathology and artificial intelligence are unlocking new possibilities for pathologists in the fight against cancer,” said David West, CEO at Proscia. “Pathology has been historically underserved by technology, and we believe that powerful software tools will push the boundaries of how modern pathology is practiced. That’s why this funding is so important. It will allow us to expand the adoption of digital pathology while creating intelligent systems that will unlock data from tissue to greatly enhance pathologists’ productivity, increase access to care, and improve the way cancer is researched, diagnosed, and ultimately treated.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Artificial Intelligence (AI) Software Platform, Cancer Detection, Digital Pathology, Oncology, Oncology Digital Health Startups, Precision Medicine Oncology, Proscia

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |